My Treatment Approach: Multiple Myeloma

home / publications / supplements / my-treatment-approach-multiple-myeloma
Sanjay V. Patel, MD, FRCOphth, of Mayo Clinic

Belantamab Mafodotin in Relapsed/Refractory Myeloma Requires Multidisciplinary Effort

Hayley Virgil
October 1st 2020
Article

Sanjay V. Patel, MD, FRCOphth, discusses the corneal-associated toxicities that can occur with belantamab mafodotin and the need for multidisciplinary management to optimally administer this agent.

David H. Vesole, MD, PhD, of John Theurer Cancer Center at Hackensack University Medical Center

Monoclonal Antibodies, ADCs, and CAR T Cells Invigorate the Myeloma Paradigm

Jessica Hergert
September 29th 2020
Article

David H. Vesole, MD, PhD, discusses the evolution of multiple myeloma treatment, and explained how other BCMA-therapies are poised to impact clinical practice.

Shaily Shah, MD, of Weill Cornell Medicine

From the Ophthalmologist’s Eye: Managing Ocular Toxicities With Belantamab Mafodotin in Myeloma

Jessica Hergert
September 25th 2020
Article

Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.

Elisabet E. Manasanch, MD, of The University of Texas MD Anderson Cancer Center

BCMA-Targeted Approaches Revolutionize Relapsed/Refractory Myeloma Treatment

Brittany Cote
September 24th 2020
Article

Elisabet E. Manasanch, MD, discusses novel BCMA-targeted modalities that are emerging in relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, of Emory University School of Medicine

Novel Combos With Belantamab Mafodotin May Move the Needle in Myeloma

Erica DiNapoli
September 24th 2020
Article

Sagar Lonial, MD, FACP, discusses the approval of belantamab mafodotin-blmf and how it addressed an unmet need in relapsed/refractory multiple myeloma.